
    
      As a part of the pharmacokinetic documentation, the metabolism and mass balance of
      14C-ABR-215050 will be studied in healthy subjects. Female healthy subjects are included in
      the study in case of expanding the indication to female forms of cancer. In this study a
      single dose of 1.0 mg of the study drug will be administered orally as a solution under
      fasted conditions. The absorption and safety profiles for the oral water solution will also
      be documented.
    
  